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ABSTRACT
Abdallah, Hagar, M. M.S., Department of Chemistry, Wright State University, 2010.
Small Molecule Caspase Inhibitors Using Isatin and Oxindole Scaffolds and a
Combinatorial Approach.

Quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh) is a
next generation broad spectrum caspase inhibitor, the effectiveness and reduced toxicity
of which can be partially attributable to the carboxyterminal O-phenoxy group as well as
the amino terminal quinolyl groups. We seek to incorporate some of these unique
recognition elements onto small molecule derived protease inhibitors with drug like
properties. Specifically, heterocyclic scaffolds such as isatins and oxindoles. Thus, isatins
bearing electron withdrawing groups on C-5 and 2,6-difluorobenzyl moieties have been
prepared by analogy to the well studied N-substituted 5-pyrrololidinylsulfonyl isatins.
Moreover, 3-benzylidene oxindole derivatives bearing these structural motifs have also
been prepared and their effectiveness as apoptosis inhibitors was examined employing
human Jurkat T cells.
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INTRODUCTION
Apoptosis, or programmed cell death, is a biological process in which individual
old or damaged eukaryotic cells are signaled to commit suicide. It is a critical process in
the maintenance of homeostasis between cell growth and cell death. As with most
biological processes, excessive activity or inactivity can have many outcomes.
Uncontrolled apoptosis has been associated with diseases such as cancer, Huntington‟s
disease, and myocardial infarctions. Unlike necrosis, apoptosis is a clean, self contained
process.1 During necrotic cell death, the cell swells and eventually bursts. Cellular debris
is left behind and can trigger an immune response; mainly inflammation.1 During
apoptosis, the cell will shrink upon itself and the DNA will fragment. The cell membrane
will also collapse and the cell will split into small apoptotic bodies. These apoptotic
bodies can then be phagocytosed by macrophages, a type of white blood cell.
During apoptosis, cell death can occur through two different signaling pathways:
intrinsically and extrinsically. In the intrinsic pathway, the signal that triggers cell death
comes from within the cell itself.2 This can result from DNA damage, heat shock, or a
defective cell cycle. This pathway involves the release of pro-apoptotic proteins from the
mitochondria. In the extrinsic pathway, the death signal comes from outside of the cell
through pro-apoptotic receptors on the cell membrane. Pro-apoptotic ligands bind to the
pro-apoptotic receptors on the cell membrane. Once cell death is signaled, whether it is
by an intrinsic or extrinsic signaling mechanism, a series of cysteinyl aspartic proteases
1

(caspases) are activated to carry out apoptosis. The purpose of this research is twofold:
1) to synthesize and characterize new, potent caspase inhibitors for biological screening
and 2) to build a combinatorial library using isatin and oxindole scaffolds that may also
have some biological activity. This work is based on previous research as well as new
insight for possible inhibitor potency and combinatorial library synthesis.

2

BACKGROUND
Recent studies have shown that caspases are critical enzymes in the activation and
execution of apoptosis. They have also been shown to play important roles in
inflammation and cytokine maturation. Within the caspase family are caspases 2, 8, 9 and
10, which are the initiator caspases. These initiator caspases are signaled by intrinsic or
extrinsic pathways of the apoptotic process and activate the effector caspases, which are
caspases 3, 6 and 7. Caspases 1, 4 and 5 are reported to be involved in inflammation, not
in apoptosis. Caspase-3 is the dominant effector caspase involved in the cleavage of
DNA repair enzymes, nuclear lamins and regulatory proteins during apoptosis.1, 2
Caspases recognize a specific tetrapeptide chain within the amino acid sequence
of the substrate (target), and that is the P4-P3-P2-P1 sequence.3 These are the peptides that
the caspase will cleave to begin apoptosis. It is very critical that the P1 residue in the
amino acid sequence be aspartic acid. For example, poly (ADP-ribose)polymerase or
PARP, is a DNA repair enzyme that contains the cleavage sequence D-E-V-D (P4-P3-P2P1) where D is aspartic acid, E is glutamic acid and V is valine as shown in Figure 1.
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Figure 1

Caspases are a class of protease enzymes which catalyze the hydrolysis of amide
bonds through nucleophilic attack by the activated cysteine thiol from the enzyme onto
the amide carbonyl bond of the amino acid. The site of cleavage by the caspase (-S3

Enzyme) is between the P1 residue and the adjacent (carboxyterminal side) P1‟ residue.
The mechanism of this nucleophilic attack is shown in Scheme 1.
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The corresponding binding sites for the P4-P3-P2-P1 residues on the substrates are
called the S4-S3-S2-S1 subsites on the caspase respectively.4 The cysteine residue of the
caspase will attack the protein as a nucleophile at the amide carbonyl leading to the
formation of a tetrahedral intermediate which upon reformation of the double bond will
result in the subsequent cleavage of the peptide bond.
Peptide derived inhibitors which utilize this mechanism of action were the first
type of caspase inhibitors studied in this field. In general, such inhibitors contain an
electrophilic functionality termed the “warhead” which can in some cases react with the
active-site cysteine residue. The warhead functionality is also very important for the
ability to bind to the caspase. There are two types of warheads, the reversible and the
irreversible functionalities. Reversible warheads are functional groups that bind to the
caspase temporarily as through a tetrahedral intermediate and can then be released; these
groups include ketones, aldehydes and nitriles. Irreversible warhead functional groups
are usually good leaving groups, so when the caspase attacks as a nucleophile, the
enzyme becomes covalently attached to the inhibitor and releasing (ideally) a non-toxic
4

and virtually harmless leaving group. Examples of irreversible warhead functional
groups are acyloxymethylketones and halomethylketones.
Several peptide inhibitors have been synthesized and studied, including two
potent inhibitors acetyl-aspartyl-glutamyl-N-(2-carboxy-1-formylethyl)-valinamide (AcDEVD-CHO)5 and quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl
ketone (Q-VD-OPh)5. Ac-DEVD-CHO (2) is an effective and widely studied caspase
inhibitor in vitro.

CO2H

O

H
N

O
N
H
CO2H

CO2H

O

H
N

N
H

O

H
O

2
Unfortunately, compound 2 has a number of undesirable characteristics, including
three CO2H groups which decrease its ability to penetrate cells for in vivo studies. Also,
the warhead functionality in this case is an aldehyde, which makes the inhibitor
reversible.

Aldehydes are also susceptible to attack by several classes of cellular

nucleophiles in the body thereby limiting specificity; additionally, this group can also
undergo oxidation.4,5 Q-VD-OPh (3), a closely related peptide inhibitor was examined
and found to have inhibition concentrations as low as 5µM.5
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3
Q-VD-OPh was found to be non-toxic to cells, even at very high concentrations
and contained an irreversible warhead functionality, the difluorophenoxy group. It was
determined that the specificity and effectiveness of Q-VD-OPh was partially due to the
difluorophenoxy warhead group.5
The broad spectrum caspase inhibitor Q-VD-OPh has been used to treat hypoxicischemic (HI) injury in the developing brain of P7 rats by Renolleau et al.6 HI injury is
directly linked to the development of apoptosis in a post-stroke brain. In this study, QVD-OPh was administered to rats of both genders after the onset of HI injury and the
effects of the drug were monitored for a period of three weeks after administration. It
was found that Q-VD-OPh greatly inhibited caspase-3 cleavage into its active p17 form,
which is the conformation of the enzyme required to initiate apoptosis. Also, these
authors found that the rats that were treated with Q-VD-OPh had significant neurological
recovery in the first 48 h of recovery time. Another interesting find was that there was a
significant difference in recovery and neuroprotection between the male and female rats.
The females were more strongly protected neurologically than the males. Moreover, the
females showed a decrease in the release of cytochrome c, a protein responsible for
apoptosis. This study indicates that Q-VD-OPh was an effective caspase inhibitor in the
central nervous system.
6

Q-VD-OPh has also been found to be an effective caspase inhibitor in Parkinson‟s
disease (PD) and Huntington‟s disease (HD) models. A study conducted by Yang et al.7
used a number of different mitochondrial toxins to model these two diseases. 1-Methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used to model PD and 3-nitropropionic
acid (3NP) and malonic acid (MA) were used to model HD.7 These neurotoxins create
lesions in the brain that model the affects of these neurodegenerative diseases. Using
mice as the test subjects, Q-VD-OPh was injected 12 h before the injection of the
neurotoxins and continued for several days. After 7 days, the mice were sacrificed and
their brains were collected for examination. In Figure 2, a difference in the levels of
neurotoxins can be clearly seen in the mesencephalons of the control mice and the mice
treated with Q-VD-OPh.

Figure 2
7

The arrows in Figure 2 show the lesions formed from the neurotoxins in the
mesencephalon.7 The control mice show large lesions while the mice injected with QVD-OPh and the neurotoxins show smaller lesions. It is clear from Figure 2 that Q-VDOPh had a significant effect in protecting the mice against neurodegeneration.
While both Ac-DEVD-CHO and Q-VD-OPh are effective caspase inhibitors, they
are not “drug-like” due to their peptide features. There are several disadvantages to
peptide based inhibitors, including the fact that they are inherently peptides and can be
metabolized in vivo; causing the drug to lack bioavailability. Also, they are relatively
large and polar molecules, making it difficult to cross the Blood Brain Barrier (BBB). It
is crucial for these inhibitors to cross the BBB for application to neurological disorders
such as Parkinson‟s disease, Alzheimer‟s and Huntington‟s disease. Peptide inhibitors
also have rapid physiological clearing times, by which they pass through the kidney and
do not come back out again.
Consideration of the limitations inherent in the use of peptide-based caspase
inhibitors for controlling cell death led to a search for potent small molecule inhibitors.
High throughput screening of the SmithKline Beecham (SKB) compound collection for
inhibitors of caspase-3 resulted in identification of 5-nitroisatins 4 and 5 which possessed
IC50s of 0.25 and 1 µM, respectively. The closely related unalkylated analogue 6 was
only slightly less active (IC50 = 3 µM).8 A correlation between the electron-withdrawing
ability of the C-5 carbon and the potency of inhibition suggested that the electrophilicity
of the C-3 carbonyl was critical for activity and that the mechanism of action involved
addition of the catalytic cysteine residue of the enzyme to this functionality.
8
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Isatin (7) is an attractive scaffold for many reasons; it is small and does not have
any peptide-like features. Also, isatin-based drugs can potentially cross the BBB due to
their relatively small size. Additionally, this scaffold allows for facile functionalization of
both the aromatic ring as well as the heterocyclic nitrogen. Alkylation of the heterocyclic
nitrogen can be performed under normal basic conditions whereas the introduction of
electron withdrawing groups (EWGs) at the C-5 position on the aromatic ring can easily
be accomplished by electrophilic aromatic substitution processes. Thus, this compound
became the lead in a drug discovery program designed to develop potent, non-peptide
caspase inhibitors. With two points of variability on the SKB lead being at the C-3 and
the C-5 positions, a combinatorial library was produced using several EWGs at the C-5
position as well as various alkylating agents for the amide nitrogen.
GlaxoSmithKline (GSK) employed the lead compound found by SKB as a
potential scaffold for a Structure -Activity Relationship (SAR) study designed to find the
optimal combination of functional groups on the scaffold.9 The first region inspected was
the C-5 region. The main goal was to find an EWG that was irreducible in vivo and could
withdraw electron density away from the C-3 region to allow for nucleophillic attack by
9

the activated cysteine residue of the caspase. While the lead compound contained a -NO2
group as the EWG, unfortunately this group can be reduced in the body to amines and
poses toxicity issues. Several different EWG on the C-5 position were synthesized and
tested for inhibition capabilities as shown in Figure 3. The inhibition concentrations
after 50% inhibition (IC50) values are reported under each compound. It is important to
note that the lower the IC50 the more potent the compound. The N-methyl isatin
compound had a fairly high IC50 value, while just adding a -NO2 group greatly increases
its potency to 1µM.9 Positioning a cyano group at the C-5 position led to an increase in
potency to 0.6 µM, whereas an iodo substituent was found to decrease activity,
presumably due to size. Finally, carboxylic acid derivatives were examined wherein the
carboxylate ester was less effective for inhibition while the carboxylate salt practically
ineffective.
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Figure 3
Further development led to the identification of the 5-N,N-dialkylisatin
sulfonamide 8 as a potential inhibitor scaffold. This functionality was seemingly ideal
10

since it incorporated an irreducible, strongly EWG at the C-5 position, while allowing for
further elaboration of the groups on the sulfonamide nitrogen so as to extend to the
crucial S2-S4 subsites responsible for determining specificity between the different
caspases.
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A group from Washington University in St. Louis (WashU) decided to build upon
the GSK-SAR study.10 They found that not only did the sulfonamide allow for various
dialkylated species, it also allowed for the incorporation of rings of different sizes.
Variation of the ring size on the sulfonamide was found to make a dramatic impact on the
IC50 values with the results shown in Figure 4.
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Figure 4
In general, based on the IC50‟s of the compounds in Figure 4, the larger the ring,
the less potent the compound becomes. Even though the azetidine ring had a lower IC50,
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the pyrrolidine ring was chosen as the optimal ring size for further studies due to the ease
of adding groups to the pyrrolidine ring via chiral proline derivatives.10 Ultimately, the
WashU group found that addition of a 2-phenoxymethyl group in the (S)-configuration on
the pyrrolidine ring resulted in an increase in potency of the resultant isatin sulfonamide
to an IC50 of 240 nM. As stated earlier, elaboration of the substituents at the C-2 position
of the pyrrolidine derivatives allows for extension into the S2-S4 pockets enabling
modulation of both potency and specificity. For example, addition of a pyridinoxymethyl
group in place of the phenoxymethyl group was also examined and the resultant
compound was found more potent than the phenoxymethyl analogues.10
The next region of interest on the C-5 isatin sulfonamides was the isatin amide
nitrogen. Alkylation of the amide nitrogen was found to greatly increase the potency of
the inhibitor, as shown in Figure 5. Adding progressively larger groups on the amide
nitrogen, such as a methyl group and a benzyl group, the inhibitor becomes progressively
more potent. Groups such as benzyl and substituted benzyl groups have been studied and
tested for caspase inhibition with much success.10 The incorporation of a pyridine ring on
the amide nitrogen was also proposed due to the success of the pyridoxymethyl ring on
the C-5 extended sulfonamide.
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Figure 5
A comparison between the phenoxymethyl analogue and the pyridoxymethyl
analogue showed increased inhibition properties for the pyridine derivatives as shown in
Table 1.
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Table 1: Comparison of Phenoxymethyl and Pyridinoxymethyl Rings
IC50 (nM)
IC50 (nM)
R
Phenoxymethyl Ring
Pyridinoxymethyl Ring
(A)
(B)
14.5

5.2

12.4

3.9

12.1

4.4

OCH3

SCH3

F
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A summary of the SAR study is presented in Figure 6. By having two main
functional sites, the WashU investigators were able to vary three different regions on
their inhibitors.
Region I:
Variable ring size

O

N

O

S

O
O

N

O

H2C

Region II:
Substituted phenyl or
pyridine ring

Figure 6

Region III:
Substitute at para-position
or a pyridine ring

The WashU group also built upon their own isatin sulfonamide scaffold by adding
a third point of variation on the C-3 carbon of isatin.10 By having an EWG at the C-5
position and a group on the amide nitrogen, this group was able to functionalize the C-3
carbonyl to form an isatin Michael acceptor (IMA) featuring a dicyano vinyl group as the
acceptor. By adding the dicyano group to the C-3 position, the specificity of the inhibitor
towards the effector caspases changed. For example, Figure 7 shows the IC50‟s of two
inhibitors, one with a carbonyl at C-3 and the other with the IMA at C-3.
N

O
S

O

O
O

N

N

O

Malononitrile
MeOH

CN

O
S

CN

O
O

N

O

Caspase-3: 27.8 + 2.5 nM
Caspase-6: 918 + 151 nM

Caspase-3: 14.5 + 1.6 nM
Caspase-6: > 5,000 nM

Figure 7
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Based on the IC50‟s of the two inhibitors in Figure 7, the IMA favored caspase-6
while the isatin analogue was more potent against caspase-3.10 Such differentiation is
important due to the fact that different diseases carry out apoptosis via different caspases.
Alzheimer‟s disease executes apoptosis via caspase-3 while Huntington‟s disease
operates mainly via caspase-6. However, as designed, there is a limitation to the IMA as
regards to further development in that the C-3 position cannot be further functionalized
beyond the two requisite cyano groups.
Previous to this, Dr. Edward Brush of Bridgewater State College introduced a
Michael acceptor onto an oxindole scaffold at the C-3 position, creating 3methyleneoxindole (9).11 The methylene oxindole scaffold 10 is very similar to isatin
(7), with the exception of a CH2 group present at the C-3 position rather than a carbonyl.
4




N

3

5
1

6

O

N

7

H

2

O

H
10

9

Since the activated cysteine residue of the caspase can be considered a “soft”
nucleophile, the corresponding “soft” -position of methylene oxindole may allow such
substrates to act as effective Michael acceptors for the inhibition of caspases as well as
other cysteine proteases.
More recently, a group in Australia discovered a new mechanism of action
between their peptide inhibitors and caspase-1.12 As mentioned earlier, the activated
cysteine thiol acts as a nucleophile, which attacks at the carbon of the warhead bearing a
leaving group and covalently bonds to the inhibitor at that site. Löser et al. showed that it
15

was not necessary to have an electrophilic warhead on the peptide inhibitor to have
inhibitory capabilities. They instead used a variety of secondary and tertiary amines as
the warhead, as shown by the secondary amine bearing a phenol ring on the C-terminal
side of the modified P1 aspartic acid group in structure 11. By doing this, they were able
to show that covalent interactions between key subsites on caspase-1 and the inhibitor
can produce potent, reversible inhibitors.12 This work is also important due to the fact that
secondary and tertiary amines are stable in vivo, meaning that the inhibitor has high
bioavailability and stability.
OH

OH

O
O

O
H
N

H
N

N
H

N
H
O

11
When tested against caspase-1, it was found that the amine nitrogen was
positioned in the substrate binding groove between the Cys 285 and the His 237 residues,
and the 2-hydroxybenzylamine was positioned in the S1‟ subsite.12 Shown in Figure 8 is
a model conformation of 11 in the active site of caspase-1. This figure demonstrates that
there is appreciable hydrogen bonding between the 2-hydroxybenzylamine and the Asp
288 residue in the S1‟ subsite, and also between the amine nitrogen and the His 237
residue as shown by the dashed lines.

16

Figure 8
This research performed by Löser et al. is significant because it proposes that
hydrogen bonding between the inhibitor and the binding site of the caspase greatly
influences the inhibition capabilities of the inhibitor. Accordingly, substituent groups
with available electrons such as hydroxyl and methoxy groups could be used as possible
groups on caspase inhibitors, contrary to prior belief.
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OBJECTIVES
Based on the previously stated research findings, the present project was to
develop, synthesize and characterize caspase inhibitors using a combinatorial approach.
As described earlier, SKB and the WashU group prepared a series of inhibitors using an
isatin scaffold with two points of variability. While more recently the WashU group
initiated studies on Michael acceptor based caspase inhibitors derived from such isatins,
such inhibitors also possess just two sites of variability. The goal of this project is to
develop benzylidene oxindole derivatives bearing three sites of diversity as potential
Michael acceptors for caspase inhibition. A structural summary of the previous and
proposed families of small molecule caspase inhibitors are shown below in Figure 9.
SmithKline Beecham

Washington Univ. St. Louis

Wright State Univ.

CN
R1

O

N
R2

O

R1

R3
CN

N

O

R2

R1

N

O

R2

Figure 9
To synthesize such a combinatorial library of oxindole derived potential Michael
acceptors for caspase inhibition, it was deemed necessary to develop a plan based on the
functionalization and utilization of both oxindole and isatin derivatives (vide infra). The
first step in the anticipated series of reactions would involve the addition of different
functionalities to the C-5 position of these substrates. To that end, the nitration of the C-5
positions of isatin and oxindole were conducted, according to Schemes 213 and Scheme
3.14
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Scheme 2
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The nitration procedure follows an Electrophilic Aromatic Substitution (EAS)
mechanism.15 In the EAS mechanism, sulfuric acid protonates nitric acid, giving off
water as a byproduct and thereby generating the actual nitronium ion electrophile. The
EAS mechanism, which is the same mechanism followed for the nitrations of both 7 and
10 is shown in Scheme 4.
Scheme 4
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Secondly, in place of the potentially reducible nitro group, a sulfonamide at the C5 position was desired. To this end, both oxindole and isatin were treated with
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chlorosulfonic acid to initially produce sulfonyl chloride derivatives, prior to treatment
with the appropriate amines as shown in Scheme 516 and Scheme 617.
Scheme 5
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The necessity of functionalizing both oxindoles and isatins stems from the fact
that oxindole cannot be alkylated regioselectively since it produces an ambident anion
which affords a mixture of N-alkyl and 3-alkyl derivatives. Thus, in order to secure Nalkylated oxindoles before the aldol reactions necessary to produce benzylidene
oxindoles, such alkylations must be performed at the isatin oxidation level. This Nalkylation must be performed before the reduction of the C-3 carbonyl of 7 to the CH2.
When the 5-substituted isatin is reduced to a 5-substituted oxindole, it will have two
possible points of alkylation, the amide nitrogen and the α-carbon. Scheme 7 shows the
possible outcomes of an alkylation reaction on 5-substituted oxindole.18
Scheme 7
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Thus, in order to secure N-alkylated oxindoles before the aldol reactions
necessary to produce benzylidene oxindoles, such alkylations must be performed at the
isatin oxidation level. Scheme 8 shows the process that will be used for the N-alkylation
of isatin. Various alkyl groups will be used to determine the best possible combination of
functional groups for optimum inhibition.
Scheme 8
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Secondly, the highly conjugated isatin anion is formed

In the first step the base abstracts a proton from nitrogen
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Final N-alkylated isatin product

The next step involves the nucleophilic attack on the alkyl halide reagent

Thus, upon C-5 functionalization, the oxindole can be treated directly with an
aldehyde to afford the desired alkylidene oxindole, or if N-substitution is desired the
corresponding N-alkylated isatin can be reduced to the oxindole by Wolff-Kishner
reduction of the C-3 carbonyl using 80% hydrazine hydrate as the reducing agent.19 The
reaction scheme is shown in Scheme 9.
Scheme 9
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This step will also be desirable due to the cost difference between isatin and
oxindole. Isatin is much cheaper than oxindole, making it the more affordable and the
economical option for the experiments. The mechanism20 for the Wolff-Kishner
reduction is shown in Scheme 10.
Scheme 10
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After reduction of the N,5-disubstituted isatin to an N,5-disubstituted oxindole, an
aldol condensation is envisioned. The aldol condensation21 is a reaction between an αcarbanion and an aldehyde. A weak base is used to abstract the α-H and the resulting
enolate anion can then act as a nucleophile to attack the carbonyl of the aldehyde
followed by a loss of water. The mechanism for this reaction is shown in Scheme 11.22

22

Scheme 11
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RESULTS AND DISCUSSION
Initial attempts at securing 5-chlorosulfonylisatin involved heating isatin (7) in
chlorosulfonic acid at 70 °C according to a literature procedure.17 However, the identity
of this compound was recently called into question by the GSK8 group, who instead
isolated a high yield of the gem-dichloro derivative (16b) as seen in Scheme 12.
Scheme 12
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In our experiment, a melting point was performed on the product and it was found
to be 137-140°C. Isatin has a melting point of ~201°C, which provides evidence that the
product is different from the starting material. Unfortunately, the literature melting
points for 5-chlorosulfonylisatin vary greatly, the earliest preparation in which the
product was recrystallized from acetone-benzene was reported to have a melting point of
150-152 oC,17 whereas more recent approaches involving treatment of 5-isatinsulfonic
acid sodium salt with phosphorus oxychloride in tetramethylene sulfone reported a
product with a melting point of 188-190 oC.9 Since we were unable to directly
chlorosulfonate isatin, and in light of the recent commercial unavailability of 5isatinsulfonic acid sodium salt, it was decided to abandon further investigations into the
study of sulfonamide isatins and their reduction to oxindoles.
Attention was then focused on the N-alkylations of isatin using KF/alumina as a
novel base and different alkylating agents.23 Whereas the literature protocols for N24

alkylation normally involve the use of CaH2 in DMF solvent, the present protocol,
employing acetonitrile as the solvent and KF/alumina as the base, would give an
opportunity for a novel approach to this well studied N-alkylation reaction. The reaction
was performed according to Scheme 13 and the data associated with these experiments
are shown in Table 2.
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Table 2: N-Alkylations of Isatin using KF/Alumina or CaH2
Experimental Literature
Compound
Base
R
Melting Point
Melting
#
(°C)
Point (°C)
F
Br
KF/alumina
178-185
N/S*
17

O
R

% Yield

37.1

F
O

18

KF/alumina

Liquid

N/S

N/A

190-197

132-13323

Starting
Material

196-199

133-13423

Starting
Material

Liquid

N/S

24.9

O
O

19

KF/alumina
O
Br

Cl
20

KF/alumina

21

CaH2

O
O

25

O

22

CaH2

124-128

132-13323

38.3

134-139

133-13423

15.1

O
Br

Cl
23

CaH2

*N/S= product has not been synthesized before in the literature.

Unfortunately, the reactions performed were largely unsuccessful, with many of
the reactions simply returning unreacted starting material, as proven by the melting points
and their similarities to the melting point of 7. The data presented in Table 2 indicates
that N-alkylations using KF/alumina are not very promising. The reactions performed to
prepare compounds 18 and 21 involved attempted Michael type acceptors instead of alkyl
halides. For the preparation of compounds 22 and 23, the literature protocol involving
CaH2 and DMF was used. From Table 2, the experimental melting points and the
literature melting points for compounds 22 and 23 are very similar, showing that the
products are in fact the predicted ones, despite the fairly low yields. Considering that the
major goal of this research was the preparation of about 10 mg of a compound for
screening, low yields were not considered an issue throughout this program of research
because biological activity took priority over yield. If the compound was screened and
found biologically active, then further experimentation would be done to increase the
overall yield.
Having decided to abandon the C-5 sulfonamide moiety, the less desirable nitro
group was then chosen as a representative EWG for our studies. Thus, a nitration
procedure was performed on isatin 7 and the melting point of the product was used to to
compare it with the literature value published by SKB,8 as shown in Scheme 14.
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Many of the procedures found in the literature for the nitration of 7 use fuming
nitric acid,24,25 which was deemed undesirable due to lab safety considerations. An
alternate procedure was found which employs potassium nitrate and concentrated sulfuric
acid.14 Using this procedure, a solution of potassium nitrate and sulfuric acid was first
prepared and cooled to 0 oC in an ice bath. A second solution of isatin and sulfuric acid
was prepared and added dropwise to the aforementioned potassium nitrate solution over a
period of 1 hr, making sure that the reaction temperature did not exceed 5 °C. The
reaction mixture was then poured over ice and the solid collected via vacuum filtration.
The melting point of the product was 249-252 °C, which was very close to the literature
melting point of 252-254 °C.14 Since this compound is known and had been shown by
SKB to be active as a caspase inhibitor, a sample of 13 was sent to Dr. Thomas L. Brown
for screening to compare the results using the Brown protocol to the SKB results. Since
the N-alkylation reactions on 7 were not as successful and an N-methyl or N-benzyl
derivative could not be produced, it was not expected that the N-unsubstituted isatin 13
would be highly active, and in the event it was found inactive in the Brown protocol at
concentrations of up to 100 M. Additionally, it was also decided to test compounds 7
and 10 to determine if any activity might be attributable to the scaffolds themselves, and
expectedly they were found inactive.
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Since at the moment it appeared that isatin derivatives with known activity were
likely to show no activity in the Brown protocol, it was decided to focus on the
benzylidene oxindoles described earlier by analogy to the Michael acceptor prepared by
Dr. Edward Brush but with the potential for more sites of variability. Recalling that the
SKB8 and WashU10 inhibitors had a maximum of two points of variability, the proposed
benzylidene oxindoles have the advantage of having three readily accessible points of
variability with the potential to tune potency and selectivity amongst various caspases.
Deciding to employ oxindole as a potential scaffold for caspase inhibitors, a
nitration procedure was then performed to add a –NO2 group at the C-5 position. Even
though this group is known to be reduced in vivo, it was decided to prepare some analogs
bearing this functionality and if activity was found due to the presence of certain groups
at the C-3 or N-position(s), another more suitable EWG at C-5 could be substituted.
Therefore, compound 12 was prepared by nitration of 10 at 0 oC employing nitric acid/
sulfuric acid as shown in Scheme 15.13
Scheme 15
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The product was recrystallized using a 50% acetic acid: water solution affording
an overall yield of 85% after recrystallization. The melting point was determined to be
244-245°C which compares well with the literature melting point of 240-241°C,
concluding that the product synthesized was indeed 12.13 Additionally, the formation of
the product was confirmed by GC/MS and NMR spectroscopic analysis. With the
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oxindole bearing a strongly EWG at the C-5 position in hand, aldol condensations using
several different aldehydes and 12 were then conducted to functionalize the C-3 position
according to Scheme 16.
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In a typical procedure, a reaction mixture of 12 (1 equiv), aldehyde (1.2 equiv),
and piperidine (0.1 equiv) in ethanol was stirred at 90 oC for 3-5 h.21 After the mixture
cooled, the precipitate was filtered, washed with cold ethanol, and dried to give the target
compounds. The aldehydes employed are shown in Table 3.

Compound #

Table 3: Aldol Condensations using 5-Nitroindolin-2-one
Experimental
Literature
E or Z
R
Melting Point Melting Point
Isomer
(°C)
(°C)

24

N
H

25

Biological
Activity

>295

308-31032

Z

negative

269-271

N/S

E

N/T

218-221

N/S

E:Z
93:6

negative

231-234

N/S

Z

N/T

Cl

26
F3C

27

29

F

28

251-255

N/S

E

negative

301-306

N/S

E:Z
75:25

negative

F

F

29
F

*N/T= product not tested for biological activity *N/S= product has not been synthesized before in the literature

The E:Z ratio of isomers in Table 3 were determined by GC/MS analysis. Upon
aldol condensation and spontaneous dehydration, the resultant benzylidene oxindoles can
exist in either the E or Z conformation (or a mixture of both). The 1H NMR spectrum of
each compound was examined very closely for subtle indicators that predict and confirm
the configuration of each product. The literature26 shows that the chemical shifts for the
C-2‟ and the C-6‟ protons in the Z isomer are more downfield (7.85-8.53 ppm) than the
C-2‟ and the C-6‟ protons in the E isomer (7.45-7.84 ppm). In general, the C-2‟ and the
C-6‟ (ortho) protons will be shifted downfield relative to the vinyl proton in the Z isomer,
and the opposite is true for the E isomer. The different structures for the E and Z isomers
are shown in Figure 10.27 To determine if the products are accurately predicted, 1H and
13

C NMR spectroscopic analyses were performed. All of the spectra generated were

analyzed and expanded using SpinWorks 3.1.
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Figure 10
There are several factors that can act to determine whether the compound will be
predominantly in the E or the Z isomer. Electrostatic interaction between the substituents
on the C-3 benzylidene ring and the C-2 carbonyl will cause the ring to be in the Z
isomer, while electrostatic repulsion will cause the ring to move into the E isomer form.27
Also, hydrogen bonding between the substituents at the different positions on the C-3
benzylidene ring and the C-2 carbonyl would also cause the products to favor the Z over
the E configuration.27
The compounds that were of most interest were those containing the 2,6difluorobenzaldehyde moiety, due to structural similarities to the Q-VD-OPh model
inhibitor. Compound 28, along with several other products from Table 3 were sent to
our collaborator Dr. Thomas L. Brown for biological screening. The biological assay is
performed to verify whether the compound being tested inhibits apoptotic cell death or
not. The tests conducted were blind tests, meaning that the researchers doing the
screening did not know what the compounds were; this eliminates any bias that may
occur. The screening was also done by different people at different times and all received
the same results. The gel for compound 28 is shown in Figure 11.
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M

V D AD 20 50 100

8 x 106 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 10µL DMSO + 10µL Methanol
D- Drug only: 10µL 50mM 28 + 10µL Methanol
AD- Actinomyocin D only: 10µL of 1µg/µL Actinomyocin D + 10µL DMSO
20- 10µL of 20mM 28 + 10µL of 1µg/µL Actinomyocin D
50- 10µL of 50mM 28 + 10µL of 1µg/µL Actinomyocin D
100- 10µL of 100mM 28 + 10µL of 1µg/µL Actinomyocin D

Figure 11
The “M” channel is the DNA marker channel, which shows the DNA strands
being tested. The “V” channel contains the solvent and the cells being tested only and no
compound 28. The Drug (D) channel is compound 28 in methanol along with the cells
being tested. The “AD” channel contains cells that are treated with the Actinomycin D
protein, which is a pro-apoptotic protein secreted from the mitochondria. The channels
that are marked with 20, 50 and 100 are the concentrations that the compound is being
tested at. The dark bands translate to inactivity, which also means the cells used for this
assay, which were Human Jurkat T cells (Type 2 cells), underwent apoptotic cell death
even at high concentrations (such as 100µM) of potential inhibitors.
While it was deemed important to determine the relative inhibitory properties of
compound 28 possessing the 2,6-difluorophenyl moiety resembling the warhead of QVD-OPh, it was also thought interesting to examine the activity of compound 29 the 3,532

difluoro substitution pattern, as this was thought to enhance the Michael acceptor
properties of the substrate. Unfortunately, compound 29 proved insoluble under the
screening conditions, so that proof of this hypothesis could not be achieved.
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It is also interesting to note that 5-nitroisatin (13) which was found active against
caspase-3 by GSK, showed no activity in the WSU screen (gel not shown). Although
there are significant differences between the literature IC50 value and the value
determined by the Brown protocol, this was determined inconsequential as we could
establish a relative scale of activity for our compounds in any case.
After a review of the screening results and careful interpretation of those results, a
change in strategy was put into effect. Since a –NO2 group demonstrated no clear
advantage and could be reduced to a toxic amine, it was decided to simply study the C-5
unsubstituted oxindoles so as to determine the role of the group at C-3. Previously, Löser
et al. had demonstrated that there was no need for an electrophilic functional group on the
inhibitor for it to be active.12 It was then decided to perform aldol condensations on
oxindole (10) using several different aromatic aldehydes with a range of electron
withdrawing as well as electron donating substituents, especially those which might have
available electron lone pairs for possible hydrogen bonding effects. Thus, 3-substituted
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indolin-2-ones were prepared by condensing indolin-2-one and aldehydes in the presence
of a base. Scheme 17 shows the reaction procedure used for the aldol condensations.21
Scheme 17
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The first procedure attempted used 10 equivalents of the base piperidine
according to one literature procedure.16 Unfortunately, the yields for these reactions were
very low at only ~20%. The second procedure used to make the same compounds used
only 0.1 equivalents (a catalytic amount) of piperidine and had much higher yields,
approximately 80%.21 Several aldehydes were used following these procedures and their
products are listed in Table 4.
Table 4: Aldol Condensations using 5-Indolin-2-one and Aldehydes
Experimental
Literature
E or Z Biological
Compound
R
Melting Point
Melting
Isomer
Activity
#
(°C)
Point (°C)
30

OH
N

31

O

32

298-301

300+28

E

negative

226-229

225-22629

E:Z
9:91

active

152-155

155-15618,30

E:Z
94:6

active

213-218

N/S

E

negative

F

33
F

34

F

202-205

N/S

E:Z
92:8

negative

35

263-265

N/S

E:Z
73:27

N/T

36

172-175

175-17630,31

E

N/T

251-252

252-25330

Z

negative

199-201

N/S

Z

N/T

207-211

N/S

E

N/T

268-270

N/S

E:Z
90:10

N/T

34

Cl

F
Cl

NO2

37

F

38
NO2

Cl

F

39

F
Cl

Cl

40
Cl
*N/T= product not tested for biological activity

*N/S= product has not been synthesized before in the literature

The E:Z ratio of isomers in Table 4 were determined by GC/MS analysis. In
assigning E or Z configuration to the compounds in the table above, the NMR analysis
conducted on compound 30, which contains a hydroxyl functionality at the C-4‟ position
on the C-3 benzylidene ring will be used as an example. In the 1H NMR spectrum, the C2‟ and C-6‟ (ortho) protons are displayed as a doublet signal centered at 7.61 ppm while
35

the vinyl proton appears as a singlet at 7.31 ppm. Therefore, the ortho protons are further
downfield than the vinyl proton, allowing assignment as the E configuration by the NMR
considerations described earlier. This 1H NMR spectrum analysis was applied to all of
the compounds synthesized throughout this research to determine E or Z configurations.
Several of the compounds synthesized in Table 4 were tested for biological
activity, including compound 33 (possessing the 2,6-difluorophenyl moiety of Q-VDOPh), the result of which is shown in Figure 12. The dark bands in the 10, 20, 50 and
100 channels in Figure 12 show that compound 33 is inactive even at the highest
concentration.
M V D AD 10 20 50 100

1x 107 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 10µL DMSO + 10µL Methanol
D- Drug only: 10µL of 50mM 33 +10µL Methanol
AD- Actinomyocin D only: 10µL of 1ug/ µL Actinomyocin D + 10µL Methanol
10- 10µL of 10mM 33 + 10µL of 1µg/µL Actinomyocin D
20- 10µL of 20mM 33 + 10µL of 1µg/µL Actinomyocin D
50- 10µL of 50mM 33 + 10µL of 1µg/µL Actinomyocin D
100- 10µL of 100mM 33 + 10µL of 1µg/µL Actinomyocin D

Figure 12
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The structure for 33 was confirmed by 1H and 13C NMR spectroscopic analysis.
To do this, the core structure (compound 10) was analyzed first using 13C NMR
spectroscopy. The 13C NMR Figure 13 shows eight signals that correspond to all eight
carbons in 10.
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Figure 13
The solvent signal, CDCl3, appears at ~77 ppm. The C-2 amide carbonyl appears
in the spectrum at 178.59 ppm. The C-3 methylene signal appears in the aliphatic region
at 36.39 ppm. The aromatic region, approximately 110-150 ppm, contains six signals for
the remaining six carbons on 10. To distinguish the aromatic CH carbons from the
quaternary carbons, a 13C DEPT 90 NMR spectrum was acquired on 10. Quaternary
carbons do not appear in any of the 13C DEPT subspectra, meaning that the spectra
should only contain four signals in the aromatic region that correspond to the four
aromatic CH‟s, which was the case. The C-8 carbon appears further downfield at 142.84
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ppm, due to its proximity to the amide nitrogen. Also, the C-9 carbon is an aromatic,
quaternary carbon. When the 13C NMR of 10 is compared to the 13C DEPT 90 spectrum,
a peak at 125.37 ppm disappears in the 13C DEPT 90 spectrum, meaning that the signal
corresponds to the quaternary C-9 carbon. The remaining four aromatic CH carbons are
as follows; C-4 at 124.50 ppm, C-5 at 122.28 ppm, C-6 at 127.91 ppm and C-7 at 109.99
ppm. These values are consistent with the values stated in the literature.33,34
After performing an aldol condensation reaction using 2,6-difluorobenzaldehyde,
the product, (E)-3-(2,6-difluorobenzylidene)indolin-2-one (33), was also analyzed using
13

C NMR spectroscopy, using the signals from 10 as the core scaffold. Figure 14 shows

the 13C NMR spectrum of 33.
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Figure 14
Based on the structure of the product, there are 13 different carbon atoms that
correspond to the 13 signals observed. The solvent used for this sample was DMSO-d6
and that signal appears at ~39.5 ppm. As can be seen from Figure 14, the C-2 carbonyl
carbon has shifted upfield to 167.53 ppm. The spectrum shows a very broad doublet of
doublet peaks at ~161 and ~158 ppm, which correspond to carbons labeled C-12 and C12‟. This broadening of the doublet peaks is due to the fluorine atoms, the first atom
splitting the carbon spectrum to create a doublet while the second fluorine splits the
spectrum again, creating a doublet of doublets. The carbon labeled C-8 does not change
position in the spectrum even after the reaction; it still appears at 143.23 ppm. The C-3
carbon, however, shifts dramatically downfield into the olefinic region, since it began as
a methylene carbon and became a double bonded quaternary carbon, which now has a
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signal at 132.29 ppm. There is also a triplet signal centered at 131.93 ppm, which
corresponds to the carbon labeled C-14. The C-14 carbon is experiencing splitting by the
fluorine atoms on the benzylidene ring, creating a triplet signal.
The C-7 carbon remains relatively unchanged with a signal at 110.12 ppm in
Figure 14. Also, a signal appears at 120.70 ppm in the 13C NMR that does not appear in
the 13C DEPT 90 NMR spectrum and this has been assigned to C-9 due to its quaternary
nature and its aromaticity, which is fairly close to the oxindole value. The 13C DEPT 90
NMR spectrum shows the CH peaks that are in the aromatic region. The carbons from
the original structure of 10 in Figure 13 are relatively in the same position, with the C-4
signal showing at 121.46 ppm, the C-5 signal appearing at 119.71 ppm and the C-6
carbon signal emerging at 130.80 ppm. The carbon labeled C-10 is a CH carbon which
appears in both spectra as a triplet at 123.09 ppm. This splitting of the C-10 signal is also
due to its proximity to the fluorine atoms. Further, the C-11 signal is split into a triplet
and is overlapped within the C-12 and C-12‟ signal, with its center peak showing at ~112
ppm.
It was very discouraging to see that compound 33 was inactive, since the initial
expectation had been that the difluorophenyl group from Q-VD-OPh would be a
successful addition to the active inhibitor library. The active compound X though, was
created by pure accident. Originally, using compound 33 as the starting material, it was
decided to nitrate the compound assuming that addition of the nitro group would occur
exclusively or predominantly at the C-5 position although there was no literature
precedent.13 Scheme 18 shows the reaction performed on 33 and the predicted product.
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F

F

F
H2SO4/HNO3 at 00C for 1hr

N
H

N
H

O

F

O2N
O

28

33

If the nitration had occurred on the C-5 position, then compound 28 would be the
final product. However, the product obtained from the nitration of benzylidene oxindole
demonstrated significant cell death inhibition. From the data in Table 3, the expected
product 28 demonstrated no inhibition of cell death, it was therefore assumed that 28
could not be the nitrated compound obtained, and that nitration had occurred elsewhere
on the molecule, perhaps even on the difluorophenyl ring. The reaction and its possible
product(s) are shown in Scheme 19. Moreover, there is a mysterious byproduct that
forms during this procedure that has a molecular weight of 282 m/z by GC/MS analysis,
while the starting material 33 has a molecular weight of 257 m/z. Therefore, there is only
one nitro group adding to the compound, giving it a total molecular weight of 302 m/z. In
the case of the byproduct, the mass difference from the expected product indicates a
possible loss of a fluorine atom perhaps by some nucleophilic aromatic substitution
process. The initial screen involved testing of a sample consisting of approximately equal
amounts of X and its defluorinated byproduct. Although it was not common practice to
screen impure mixtures, failed initial attempts to purify the sample and in the interests of
time, an answer as to the potency of the 2,6-difluorophenyl group was needed and if it
were highly active, even a mixture would demonstrate cell death inhibition.
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The biological assay performed on compound X is shown in Figure 15. As can
be seen in Figure 15, compound X was 100% active at 100 µM and about 50% active at
50 µM, even in its impure state.

8.45 x 106 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 10µL DMSO
F- α Fas only: 2µL of α Fas (clone C-11) 100ng/mL[Final] + 10µL DMSO
20- 10µL of 20mM X+ 2µL of α Fas (clone C-11) 100ng/mL[Final]
50- 10µL of 50mM X + 2µL of α Fas (clone C-11) 100ng/mL[Final]
100- 10µL of 100mM X + 2µL of α Fas (clone C-11) 100ng/mL[Final]

Figure 15
Subsequent to this initial screening result, column chromatography was employed
to separate the unwanted byproduct and to afford progressively pure compound X (MW =
302). This was a very long and tedious process because the active compound and its
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byproduct are very similar in polarity by TLC. Figure 16 shows the gel performed on a
more purified version of compound X. It is seen from Figure 16 that the compound was
100% active at 20 µM concentration.

6.4x 106 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 10µL of DMSO & 10µL of Methanol
D- Drug: 25µL Q-VD-OPh
AD- 10µL of AD
20- 10µL of X & 10µL of AD
50- 25µL of X & 10µL of AD
100- 50µL of X & 10µL of AD

Figure 16
Several methods were used to purify compound X, including prep TLC, liquid
chromatography and standard column chromatography. Finally, after several purification
procedures, compound X was isolated and shown to be pure by GC/MS analysis and 1H
and 13C NMR spectral analyses. Figure 17 shows the gel performed on the purest form
of compound X.
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1.28 x 106 cells/ml of Jurkat cells
M- Marker
AD- Actinomyocin D only: 10µL of 1µg/µL Actinomyocin D + 10µL Methanol
5- 10µL of 5mM X + 10µl of 1µg/µL Actinomyocin D
10- 10µL of 10mM X + 10µl of 1µg/µL Actinomyocin D
20- 10µL of 20mM X + 10µl of 1µg/µL Actinomyocin D

Figure 17
Pure X was active at an astonishingly low concentration of 5 µM. This was a
very promising result, since the commercially available Q-VD-OPh is also active at 5
µM.5 It was also important to determine whether compound X was inhibiting apoptosis
via caspases or not, and/or which caspase it was actually inhibiting. To do this,
compound X was tested against other cysteine proteases. Cathepsins, which are cysteine
proteases as well, are also responsible for carrying out apoptosis.35 Cathepsins are
synthesized in the lysosome of the cell as inactive enzymes called zymogens and are
released when an intrinsic or extrinsic cell death signal is given.35 The test against
cathepsin L, which is the most common cathepsin secreted upon distress, was done by
Dr. Scott Diamond and Dr. Tianhua from the University of Pennsylvania‟s Institute for
Medicine and Engineering in Philadelphia, Pennsylvania. The testing was done on a
blind basis, meaning that the personnel doing the testing did not know what the
compounds were and that the compounds are tested twice for comparison purposes. The
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compounds that were tested were compound X and compound 33. For compound X, the
result was an IC50 of 43µM against cathepsin L, which means that compound X is not a
very active inhibitor of cathepsin L. Compound 33 tested negative.
Testing was also done against another class of cysteine proteases called calpains,
which are also involved in signaling for apoptosis.36,37 Calpains are activated when there
is an increase in the Ca2+ ion concentration in the cytosol of the cell.37 The calpain testing
was done by Dr. Andrew Abell and Dr. Ondrej Zvarec from the School of Chemistry and
Physics at The University of Adelaide in Adelaide, Australia. The testing was also done
blindly and they too tested compounds 33 and X. The results from the calpain test show
an IC50 of 3.3µM calpain inhibition for compound X, meaning that it is an average
calpain inhibitor. The results from these two tests show that compound X is an average
inhibitor of cathepsins and calpains. This is promising because for compound X to be
caspase specific, it cannot be very active against other cysteine proteases. This would
make it non-specific and therefore non-usable as a drug. The experiment that has yet to
be done is to test compound X against the different caspases to see which one it is
actually inhibiting and by which pathway.
Now that the inhibition activity was shown to be very effective, it was necessary
to determine the actual structure of the inhibitor X. There were two possible areas that
the nitro group would be expected to attack, the C-3 benzylidene ring or the aromatic
portion of the heterocyclic oxindole ring. To determine the carbon most likely to be
attacked by the electrophilic nitronium ion, ChemDraw Ultra was used to predict the 13C
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NMR shifts of the starting material 33. Figure 18 shows the ChemDraw predictions of
the 13C NMR shifts of 33.
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Figure 18
The carbon with the lowest value (ppm) will be the most likely place of nitration,
being the most electron rich site on the compound. From Figure 18, the carbon with the
highest electron density would be ortho to the fluorines on the C-3 benzylidene ring.
This makes sense because fluorines are electronegative and will pull electron density
away from the adjacent carbons and towards themselves by inductive effects, but are
reasonably strong electron donors via resonance. With that in mind, an alternate
synthesis was planned. The original procedure from Scheme 19 was a very tedious
procedure and an unwanted byproduct was formed every time the synthesis was
performed. Scheme 20 and Scheme 21 show the new synthetic path expected to form
compound X. Thus, 2,6-difluorobenzaldehyde (41) was nitrated using a literature
procedure as shown in Scheme 20.38 The product 42 was then condensed to 10 by an
aldol condensation to afford 43 as shown in Scheme 21.
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Compound 42 was synthesized with relative ease and a yield of 17%. The
reaction from Scheme 21 gave product 43 with a yield of 12%. Product 43 was pure by
TLC and GC/MS analysis did not show any signs of the 282 m/z byproduct that had been
formed in the previous synthesis. The structure of compound 43 was confirmed by
GC/MS and 13C NMR spectroscopic analyses. The 13C NMR spectrum for compound 43
is shown in Figure 19.
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Figure 19
The 13C NMR spectrum of 43 is different from the 13C NMR of compound X,
which raised some concern as to whether this compound was in fact the active compound
X. In Figure 19, there are 15 signals that correspond to all of the signals in the structure
of compound 43. All of the signals in Figure 19 are singlet peaks, while in the spectrum
of compound X (not shown), the signals are experiencing different splitting patterns into
doublets and triplets. There is also a difference in the number of signals between the two
compounds 43 and X, which is a definitive indicator that the compounds are not the
same. To determine whether compound 43 is active or not, a sample of it was sent to Dr.
Brown for biological screening. The gel for compound 43 is shown in Figure 20. The
compound had tested negative, even at 100 µM.
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7.0 x 106 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 20µL DMSO & 10µL CH3OH
AD- Actinomycin D: 10µL AD
20- 4µL of 43 & 10µL AD
50- 10µL of 43 & 10µL AD
100- 20µL of 43 & 10µL AD

Figure 20
At this point, a pressing question arose as to what might be the actual structure of
active compound X? Obviously the ChemDraw prediction of relative electron density of
compound 33 (Figure 18) which indicated the most likely site of nitration was ortho to
the fluorines was not correct otherwise compound 43 would have been active. It was
then decided to take a closer look at the 13C NMR spectra of the precursor 10 of the
active compound X. An examination of the spectra of 10 (Figure 13), indicates that the
carbon with the highest electron density is C-7, which has a signal at 109.99 ppm; a value
which is consistent with the literature assignment.34 Moreover, after a reaction with 2,6difluorobenzaldehyde to form compound 33, C-7 is still the most electron rich carbon
with its signal at 110.12 ppm as shown in Figure 14. For comparison, the carbons
adjacent to the fluorines, C-12 and C-12‟are a doublet peak centered at ~112 ppm
indicating that C-7 is the most electron rich carbon in compound 33. Based on this
interpretation of the 13C NMR spectrum, the point of nitration on compound 33 would
49

most likely be C-7 and not C-12 or C-12‟. To prove or disprove this theory, it was
necessary to either prepare or purchase 7-nitrooxindole (45) and conduct its reaction with
33. Purchasing 45 was economically prohibitive, since it is a custom synthetic
compound. Examination of the literature revealed a procedure to synthesize 45 from 8nitroquinoline (44).39,40,41 The procedure involves using 30% H2O2 and acetic acid to
oxidize 44 to form 45 through a proposed lactone intermediate.42 This reaction procedure
is shown in Scheme 22.
Scheme 22
H2O2 (30%), AcOH
70 oC for 8 h
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This reaction was performed under moderate conditions with relative ease. The
yield of compound 45 was 14%, which was comparable to the literature yield of 20%.42
Using 45 as the starting material, an aldol condensation was performed using 41 to form
46. This procedure is shown in Scheme 23.
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Reviewing again, compound 46 was synthesized due to its likelihood of being the
actual active compound X based on a consideration of the electron density at C-7 based
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on 13C NMR shifts. Unfortunately the results of the biological activity were not available
by the time of the thesis defense.
While the initial goal of this project was to employ some of the structural features
of Q-VD-OPh, the difficulties presented by the use of the 2,6-difluorophenyl substituent
in terms of the defluorinated byproduct led us to examine a number of other possible aryl
aldehydes in search of activity. In this regard, it is interesting to note that a 4-methoxy
group on the aryl ring at the C-3 position demonstrated a low level of activity. This is
noteworthy since our working hypothesis entailed nucleophilic attack by the cysteine
residue of caspases on the -carbon of the benzylidene oxindoles and a para-methoxy
would be expected to reduce the electrophilicity of this position. Thus, the marginal
activity of compound 32 (~50µM) came as somewhat of a surprise. The gel for active
compound 32 is shown in Figure 21. The fact that this compound demonstrates may thus
be an example of the non-electrophilic type of warhead suggested by Löser et al.12
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4 x 106 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 20µL DMSO & 10µL Methanol
D- Drug: 20 µL of 32
AD- 10 µL AD
20- 4µL of 32 & 10µL AD
50- 10µL of 32 & 10µL AD
100- 20µL of 32 & 10µL AD

Figure 21
The 13C NMR spectrum of compound 32 is shown in Figure 22.
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Figure 22
The product 32 was confirmed by 1H and 13C NMR spectroscopic analysis.
Figure 22 shows 14 signals in the 13C NMR NMR that correspond to the structure for
active compound 32. The solvent used for this spectrum was DMSO-d6, which appears at
~39.5 ppm. As can be seen, there is a peak in the aliphatic region at 55.26 ppm, which
corresponds to the CH3 of the methoxy group on C-15 while the C-2 amide carbonyl
appears at 168.93 ppm. Also, the aromatic carbon bearing the methoxy group appears
downfield with a signal at 160.48 ppm. Further examination of the other peaks in the
aromatic region utilized 13C DEPT 90 NMR to distinguish between the CH aromatic
carbons and the quaternary aromatic carbons. The signal at 142.65 ppm appears in the
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13

C NMR spectrum but not in the 13C DEPT 90, meaning that it corresponds to the

quaternary carbon labeled C-8. The signal at 135.94 ppm is present in both spectra,
meaning that it is an aromatic CH carbon that corresponds to C-10. There are two intense
signals that are also present in both spectra. They appear at 131.42 ppm and 114.17 ppm.
The first signal can be identified as C-12 and C-12‟ as they are symmetrical CH carbons
and the second signal is identified as C-13 and C-13‟ as they too are symmetrical
carbons.
The original CH carbons on 10 do not shift very much from their original
positions: C-4 at 122.02 ppm, C-5 at 120.95 ppm, C-6 at 129.58 ppm and C-7 at 109.98
ppm. The remaining quaternary aromatic carbons have lower intensity signals and are
not visible in the 13C DEPT 90 NMR. These are carbons C-3, C-9 and C-11. Carbon C-3
has a signal at 121.17 ppm, which is a dramatic shift downfield from the original
oxindole (10) C-3 carbon. Carbon C-9 does not shift very much from its original position
in 10, with its signal at 125.61 ppm. The C-11 carbon signal is very close to C-9 with its
signal showing at 126.59 ppm.
Finally, the third active compound might in some way be considered as
mimicking the structural features of Q-VD-OPh in that it incorporates a pyridine ring
which resembles the quinoline ring of the peptide inhibitor. Compound 31, which has a
nitrogen atom with an available lone pair of electrons at the C-4‟ position was found
active at ~20 µM concentration. Hydrogen bonding between 31 and the active site on the
caspase could be the mechanism of action of this non-electrophilic inhibitor. The gel for
compound 31 is shown in Figure 23.
54

4.4 x 106 cells/ml of Jurkat cells
M- Marker
V-Vehicle: 20µL DMSO & 10µL CH3OH
D- 20µL of 31
AD- Actinomycin D: 10 µL AD
20- 4µL of 31 & 10µL AD
50- 10µL of 31 & 10µL AD
100- 20µL of 31 & 10µL AD

Figure 23
The structure for compound 31 could not be determined definitively by 13C NMR
spectroscopy due to it being a mixture of the E and Z configurations. The major isomer
was determined by the melting point and its proximity to either of the two isomer‟s
literature melting points.29 Both the 13C and 1H NMR spectra have double the amount of
signals expected for compound 31.
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FUTURE WORK
There is still a lot of work to be done to be able to say that an active and effective
caspase inhibitor has been synthesized. More derivatives of the active compounds X, 31
and 32 need to be made to optimize the groups at the different positions and maximize
inhibition capabilities. Hopefully compound X, once it is fully characterized and the
synthesis is solid and repeatable with good yields, can be taken even further than just in
vitro testing. I would like to see it tested on small animals and from there, go into clinical
trials if it is safe and effective. As of now, I believe that my work has led to new ideas
and new leads to pursue further. Beginning a project that no one has done before and
achieving three active compounds in two years I believe is an accomplishment.
I would also like to see these active compounds tested against other apoptotic
mechanisms. In this work, the testing was done against Human Jurkat T cells (Type 2
cells) by Dr. Thomas L. Brown. Testing these compounds against other apoptotic cells
that may not be as common or as well known, such as retinal cells (in the eye) would be
interesting to study. Retinal cell death is an area where small molecule apoptotic
inhibitors have not been studied before, so it would broaden the scope of the use of these
small molecule inhibitors as well.
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EXPERIMENTAL
Chemical Analysis
Melting points were determined via the use of open capillaries with an Electrothermal
melting point apparatus and are reported uncorrected. Elemental analyses were
performed by Midwest Microlab, Indianapolis, IN. Elemental analysis results are within
+0.4% of the theoretical values. The 1H and 13C NMR data were obtained on a Bruker
Avance 300 MHz NMR in CDCl3 solution unless otherwise indicated. The chemical
shifts are reported in δ (ppm) downfield from tetramethylsilane as an internal standard;
coupling constants (J) are in Hz. The following abbreviations are used to describe peak
patterns where appropriate: s, singlet; d, doublet, dd, double doublet; t, triplet; q, quartet;
dt, double triplet; m, multiplet. GC/MS measurements were performed using HewlettPackard 6890 Series GC with auto injection and mass fragments are reported as mass per
charge, m/z. The GC was coupled with a mass spectrometer with a Hewlett-Packard
5973 mass selective detector/quadrupole system. Flash column (Silica Gel, Premium Rf,
200-400 mesh, Sorbent Technologies) and thin layer chromatography (TLC) were
performed on silica gel with indicated solvent systems. All glassware and syringes were
oven-dried for the reactions which require anhydrous conditions. The multimode
microwave used for solventless reactions on silica gel was a GE JES638WF 700 Watt
domestic microwave with a turn table with time and power controls. All microwave
reactions were performed in a monomode Biotage Emery‟s Creator 300 Watt system and
the MARS Glasschem 300 Watt system by CEM. It should be noted that all reactions
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were run with sample absorption set to “normal”. Multiple reactions were carried out
using the FIRSTMATE system by Argonaut Technologies.

Biological Analysis
Human Jurkat T cells were treated with vehicle (V) or 1 mg/ml actinomycin D for four
hours. DNA was isolated, and analyzed on a 1.2% agarose gel stained with ethidium
bromide to determine DNA laddering. The agarose gel showed 50% functionality at 100
mm, resulting well below the inhibitory effects at 200 mm. Cytoplasmic DNA is small
(less than 1500 bp) and is generated in apoptotic cells and can cross the nuclear
membrane into the cytosol. If concentrations of the DNA are less than 200 mm, then cell
inhibition is not justified.

5-Nitroindolin-2-one (12)
To a 25-mL Erlenmeyer flask in an ice bath containing sulfuric acid (1.9231 mL) and 10
(0.5121 g, 0.0038 mol) was added nitric acid (0.1615 mL) drop-wise with stirring. The
mixture was stirred for 30 min after which the mixture was poured over ice. A brown
colored solid (0.6030 g) was collected via vacuum filtration. Recrystallization using 50%
acetic acid: water gave the pure product (beige color) (0.5621 g, 82%); mp 244-245 oC
(lit. mp 240-241 oC)13; Rf = 0.55 (EtOAc); 1H NMR (300 MHz, DMSO-d6) 11.05 (s,
1H) 8.15 (d, J = 8.6 Hz, 1H), 8.09 (s, 1H), 6.97 (d, J = 8.6 Hz, 1H), 3.63 (s, 2H); 13C
NMR : 176.65, 150.24, 141.69, 127.00, 124.86, 119.95, 108.92, 35.56 ppm.
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5-Nitroindoline-2,3-dione (13)
A solution of 7 (0.5 g, 3.4 mmol) in concentrated sulfuric acid (3.2 mL) was added
dropwise to a solution of potassium nitrate (0.344 g, 3.4 mmol) in concentrated sulfuric
acid (3.8 mL) in a 25-mL Erlenmeyer flask over a period of 1 h in an ice bath. The
reaction mixture was poured over ice. The yellow-orange solid was collected via vacuum
filtration (0.441 g, 67.5%). mp = 249-252°C (lit mp = 252-254 °C)14; Rf = 0.71 (EtOAc);
1

H NMR (300 MHz, DMSO-d6)  11.67 (s, 1H), 8.45 (d, J = 8.71 Hz, 1H), 8.22 (s, 1H),

7.10 (d, J = 8.72 Hz, 1H)

1-(2,6-Difluorobenzyl)indoline-2,3-dione (17)
In a vial with acetonitrile (3 mL) was dissolved isatin (0.3 g, 0.00204 mol) and
KF/Alumina (1 equiv, 0.1185 g, 0.00204 mol). 2,6-Difluorobenzyl bromide (2 equiv,
0.8446 g, 0.00408 mol) was added to the vial. The vial was placed on a 30 °C hot plate
for 5 days. The vial was then heated at 50 °C for 48 h. Deionized water was added to the
vial and stirred for 6 days at room temperature. Bright orange solid was collected via
vacuum filtration (0.2066 g, 37.1 %). mp = 178-185 oC; Rf = 0.89 (EtOAc); 1H NMR
(300 MHz, DMSO-d6) 7.60 (d, J = 6.60 Hz, 1H), 7.53 (dt, J = 7.82 Hz, 1H), 7.36-7.27
(m, 1H), 7.31 (t, J = 6.55 Hz), 7.10 (t, J = 7.35 Hz, 1H), 6.94 (t, J = 8.20 Hz, 1H), 5.03,
(s, 1H).
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Attempted Synthesis of (18)
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina
(1 equiv, 0.1185 g, 0.00204 mol). Ethyl acrylate (2 equiv, 0.4085 g, 0.00408 mol) was
added to the vial. The vial was placed on a 30°C hot plate for 5 days. The vial was then
heated at 50 °C for 48 hrs. Deionized water was added to the vial and stirred for 6 days
at room temperature. The product was an oily substance. The synthesis yielded only
starting material based on the melting point.

Attempted Synthesis of (19)
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina
(1 equiv, 0.1185 g, 0.00204 mol). Ethyl bromoacetate (2 equiv, 0.6814 g, 0.00408 mol)
was added to the vial. The vial was placed on a 30°C hot plate for 5 days. The vial was
then heated at 50 °C for 48 hrs. Deionized water was added to the vial and stirred for 6
days at room temperature. The product was an oily substance (0.2168 g, 45.6 %). mp =
190-197 oC (lit mp = 132-133 °C)23; Rf = 0.83 (EtOAc). The synthesis yielded only
starting material based on the melting point.
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Attempted Synthesis of (20)
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina
(1 equiv, 0.1185 g, 0.00204 mol). Benzyl chloride (2 equiv, 0.5165 g, 0.00408 mol) was
added to the vial. The vial was placed on a 30°C hot plate for 5 days. The vial was then
heated at 50 °C for 48 hrs. Deionized water was added to the vial and stirred for 6 days
at room temperature. The product (bright orange) was collected by vacuum filtration
(0.2251 g, 46.5 %). mp = 196-199 oC (lit mp = 133-134 °C)23; Rf = 0.63 (EtOAc). The
synthesis yielded only starting material based on the melting point.

tert-Butyl 3-(2,3-dioxoindolin-1-yl)propanoate (21)
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina
(1 equiv, 0.1185 g, 0.00204 mol). t-Butyl acrylate (2 equiv, 0.5229 g, 0.00408 mol) was
added to the vial. The vial was placed on a 30 °C hot plate for 5 days. The vial was then
heated at 50 °C for 48 h. Deionized water was added to the vial and stirred for 6 days at
room temperature. A silica gel column was performed using 70:30 Hexanes: EtOAc to
afford an orange- red oil. (0.14 g, 24.9%) mp = N/A; Rf = 0.83 (EtOAc); 1H NMR (300
MHz, DMSO-d6)  7.68 (t, J = 15.6 Hz, 1H), 7.56 (d, J = 7.41 Hz, 1H), 7.25 (d, J = 7.96
Hz, 1H), 7.14 (t, J = 15.0 Hz, 1H), 3.89 (t, J = 14.1 Hz, 2H), 2.60 (t, J = 14.1 Hz, 2H),
1.35 (s, 3H).
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Ethyl 2-(2,3-dioxoindolin-1-yl)acetate (22)
Compound 7 (2 g, 13.6 mmol) and CaH2 (1 equiv, 0.5720 g, 13.6 mmol) were dissolved
in DMF (6.61 g) in a vial and stirred at 100°C for 1 h. The solution was cooled to 40°C
so that ethyl bromoacetate (3 equiv, 6.812 g, 40.8 mmol) could be added to the vial. The
vial was placed back on the hot plate at 100°C for 4h then cooled to room temp. The
solution was poured into an aqueous solution of 0.5 M HCl (40 mL) stirring vigorously.
Orange precipitate was collected via vacuum filtration. Product was recrystallized using
a 50% DCM/hexanes solution to afford a yellow product (1.2139 g, 38.3%). mp = 124128°C (lit mp = 132-133 °C)23; Rf = 0.70 (EtOAc); 1H NMR (300 MHz, DMSO-d6) 
7.69 (t, J = 15.5 Hz, 1H), 7.62 (d, J = 7.39 Hz, 1H), 7.19 (t, J = 16.6 Hz, 1H), 4.63 (s,
2H), 4.18 (q, J = 14.17 Hz, J = 7.07 Hz, 2H), 1.22 (t, J = 14.2 Hz, 3H)
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1-Benzylindoline-2,3-dione (23)
Compound 7 (2 g, 13.6 mmol) and CaH2 (1 equiv, 0.5720 g, 13.6 mmol) were dissolved
in DMF (6.61 g) in a vial and stirred at 100°C for 1 h. The solution was cooled to 40°C
so that benzyl chloride (3 equiv, 5.165 g, 40.8 mmol) could be added to the vial. The vial
was placed back on the hot plate at 100°C for 4h then cooled to room temp. The solution
was poured into an aqueous solution of 0.5 M HCl (40 mL) stirring vigorously. Red
precipitate was collected via vacuum filtration. Product was recrystallized using a 50%
DCM/hexanes solution to afford an orange product (0.486 g, 15.1%). mp = 134-139°C
(lit mp = 133-134 °C)23; Rf = 0.86 (EtOAc); 1H NMR (300 MHz, DMSO-d6)  7.66 (d, J
= 7.31 Hz, 1H), 7.57 (d, J = 6.65 Hz, 1H), 7.21 (t, J = 14.1 Hz, 1H), 6.98 (d, J = 8.18 Hz,
1H), 6.72 (t, J = 17.9 Hz, 1H), 6.57 (t, J = 14.7 Hz, 1H), 6.50 (t, J = 14.9 Hz, 1H), 4.91
(s, 2H).
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(Z)-3-((1H-pyrrol-2-yl)methylene)-5-nitroindolin-2-one (24)
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol)
with pyrrole-2-carboxaldehyde (1.2 equiv, 0.2161 g, 0.00228 mol) and piperidine (0.10
equiv, 0.0194 g, 0.000228 mol) and EtOH (2 mL). The reaction tube was placed in the
holder and the system was set to the following parameters: interval = 5, up stroke = 4,
speed = max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Reddish-brown
solid (0.4658 g, 96.1%) was collected via vacuum filtration: mp = >295 °C (lit mp = 308310 °C)32; Rf = 0.77 (EtOAc); 1H NMR (300 MHz, DMSO-d6)  11.49 (s, 1H), 8.53 (d, J
= 2.17 Hz, 1H), 8.09 (s, 1H, Hvinyl), 8.04 (dd, J = 8.61 and 2.23 Hz, 1H), 7.44 (s, 1H),
7.01 (d, J = 8.61 Hz, 1H), 6.41 (dd, J = 5.8 and 2.24 Hz, 1H).

(E)-3-(2-chlorobenzylidene)-5-nitroindolin-2-one (25)
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol)
with 2-chlorobenzaldehyde (1.2 equiv, 0.3258 g, 0.00228 mol) and piperidine (0.10
equiv, 0.0194 g, 0.000228 mol) and EtOH (2 mL). The reaction tube was placed in the
holder and the system was set to the following parameters: interval = 5, up stroke = 4,
speed = max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Green-yellow
solid (0.1148 g, 20.1%) was collected via vacuum filtration: mp = 269-271 °C; Rf = 0.74
(EtOAc); Compound 25 would not dissolve in any of the deuterated NMR solvents,
therefore an NMR spectrum could not be generated.
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(E)-3-(2-(trifluoromethyl)benzylidene)-5-nitroindolin-2-one (26)
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol)
with trifluoro-o-tolualdehyde (1.2 equiv, 0.4151 g, 0.00228 mol) and piperidine (0.10
equiv, 0.0194 g, 0.000228 mol) and EtOH (2 mL). The reaction tube was placed in the
holder and the system was set to the following parameters: interval = 5, up stroke = 4,
speed = max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Yellow solid
(0.2922 g, 46.0%) was collected via vacuum filtration: mp = 218-221 °C; Rf = 0.75
(EtOAc); 1H NMR (300 MHz, DMSO-d6)  11.46 (s, 1H), 7.97 (d, J = 7.59 Hz, 1H), 7.90
(s, 1H), 7.86 (s, 3H), 7.83-7.78 (m, 1H), 7.60 (s, 1H, Hvinyl), 7.06 (d, J = 8.69 Hz, 1H, C6‟).

(Z)-3-(3-methylbutylidene)-5-nitroindolin-2-one (27)
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol)
with isovaleraldehyde (1.2 equiv, 0.2205 g, 0.00228 mol) and piperidine (0.10 equiv,
0.0194 g, 0.000228 mol) and EtOH (2 mL). The reaction tube was placed in the holder
and the system was set to the following parameters: interval = 5, up stroke = 4, speed =
max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Off-white solid (0.2894 g,
61.9%) was collected via vacuum filtration: mp = 231-234 °C; Rf = 0.68 (EtOAc); 1H
NMR (300 MHz, DMSO-d6) 10.80 (s, 1H), 7.77 (s, 1H, Hvinyl), 6.86 (d, J = 8.66 Hz,
1H), 6.60 (d, J = 11.18 Hz, 1H), 6.40 (d, J = 7.46 Hz, 2H), 3.70 (d, J = 11.73 Hz, 2H),
1.85-1.53 (m, 1H), 1.18 (s, 3H).
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(E)-3-(2,6-difluorobenzylidene)-5-nitroindolin-2-one (28)
In a vial was combined 12 (0.4023 g, 0.0022 mol) with 2,6-difluorobenzaldehyde (1.2
equiv, 0.3837 g, 0.0027 mol) and piperidine (0.10 equiv, 26.7µL, 0.00027 mol) and
EtOH (4 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. Product was
recrystallized using acetic acid to afford a yellow solid (0.6062 g, 89%) collected via
vacuum filtration; mp = 251-255 °C; Rf = 0.78 (EtOAc); 1H NMR (300 MHz, DMSO-d6)
(s, 1H), 8.75 (s,1H), 8.21 (d, J = 8.7 Hz, 1H), 7.75-7.66 (m, 1H), 7.57 (s, 1H,
Hvinyl), 7.36 (t, J = 8.34 Hz, 1H), 7.16 (t, J = 7.99 Hz, 1H), 7.07 (d, J = 8.69 Hz, 1H); 13C
NMR : 167.77, 161.27-157.86 (dd, J = 7.24 Hz), 148.86, 141.87, 133.03 (t, J = 10.51
Hz), 130.16, 127.20, 123.31, 120.89, 118.30, 112.48- 112.46 (dd, J = 6.41 Hz), 111.44111.20 (t, J = 8.71 Hz), 110.27 ppm.

(E)-3-(3,5-difluorobenzylidene)-5-nitroindolin-2-one (29)
In a vial was combined 12 (0.1238 g, 0.00067 mol) with 3,5-difluorobenzaldehyde (1.2
equiv, 0.1150 g, 0.00081 mol) and piperidine (0.10 equiv, 0.069 g, 0.000081 mol, 10.4
L) and EtOH (1 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 hrs.
Golden solid (0.1075 g, 53.1%) was collected via vacuum filtration: mp = 301-306 °C; Rf
= 0.72 (EtOAc); 1H NMR (300 MHz, DMSO-d6)  11.37 (s, 1H), 8.53 (s, 1H), 8.14-8.02
(m, 1H), 7.71 (s, 1H, Hvinyl), 7.02 (d, J = 8.72 Hz, 1H, C-2‟), 6.96 (d, J = 8.53 Hz, 1H),
2.51 (s, 1H).
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(E)-3-(4-hydroxybenzylidene)-indolin-2-one (30)
In a vial was combined 10 (0.2500 g, 0.0019 mol) with 4-hydroxybenzaldeyhde (1.2
equiv, 0.2860 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH
(2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow solid
(0.2706 g, 60%) was collected via vacuum filtration: mp = 298-301 °C (lit mp = 300+
°C)28; Rf = 0.43 (50:50 Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.91 (s,
1H), 8.10 (d, J = 7.67 Hz, 1H), 8.03 (d, J = 8.47 Hz, 1H), 7.96 (s, 1H), 7.61 (d, J = 7.63
Hz, 1H, C-2‟), 7.31 (d, J = 13.78 Hz, 1H), 7.31 (s, 1H, Hvinyl), 7.27 (d, J = 4.69 Hz, 1H);
C NMR : 169.46, 159.67, 142.86, 132.17, 129.77, 125.41, 125.07, 122.41, 121.70,
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121.38, 116.31, 110.32 ppm.

(Z)-3-((pyridin-4-yl)methylene)indolin-2-one (31)
In a vial was combined 10 (0.2508 g, 0.0019 mol) with 4-pyridinecarboxaldehyde (1.2
equiv, 217 µL, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH
(2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow solid
(0.2524 g, 60%) was collected via vacuum filtration: mp = 226-229 °C (lit mp = 225-226
°C)29; Rf = 0.12 (50:50 Hexanes:EtOAc); Compound 31 was a mixture of E and Z
isomers, therefore an NMR spectrum could not be determined.
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(E)-3-(4-methoxybenzylidene)indolin-2-one (32)
In a vial was combined 10 (0.2532 g, 0.0019 mol) with p-anisaldehyde (1.2 equiv, 280
µL, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) with
stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.1463 g, 31%)
was collected via vacuum filtration: mp = 152-155 °C (lit mp = 156-157 °C)18,30; Rf =
0.17 (50:50 Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.56 (s, 1H), 7.67 (t, J
= 8.92 Hz, 1H), 7.59 (s,1H, Hvinyl), 7.20 (t, J = 7.51 Hz, 1H), 7.06 (d, J= 8.07 Hz, 1H, C2‟), 6.87 (t, J = 5.99 Hz, 1H), 6.83 (s, 1H), 2.50 (s, 3H); 13C NMR : 168.93, 160.48,
142.65, 135.94, 131.42, 129.59, 126.59, 125.61, 122.02, 121.16, 120.95, 114.17, 109.98,
55.26 ppm.

(E)-3-(2,6-difluorobenzylidene)indolin-2-one (33) (Procedure 1)
In a vial was combined 10 (0.25 g, 0.0019 mol) with 2,6-difluorobenzaldehyde (1.1
equiv, 0.2984 g, 0.0021 mol) and piperidine (10 equiv, 1.7882 g, 0.021 mol) and EtOH (2
mL). The vial was placed on a 70°C hot plate for 48 h. Yellow solid (0.1032 g, 21.1%)
was collected via vacuum filtration. mp = 220-223°C; Rf = 0.65 (EtOAc); 1H NMR (300
MHz, DMSO-d6) 10.73 (s, 1H), 7.67-7.57 (m, 1H), 7.34 (d, J = 14.5 Hz, 1H), 7.30 (d,
J = 16.4, 1H), 7.24 (s, 1H, Hvinyl), 6.89 (dd, J = 15.3 and 7.5 Hz, 1H); 13C NMR :
167.53, 161.32-157.92 (dd, J = 7.02 Hz), 143.23, 132.29, 131.93 (t, J = 10.44 Hz),
130.80, 123.09, 121.46, 120.70, 119.71, 112.25- 111.75 (d, J = 24.64 Hz), 112.16111.75 (t, J = 19.74 Hz), 110.12 ppm.
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(E)-3-(2,6-difluorobenzylidene)indolin-2-one (33) (Procedure 2)
In a vial was combined 10 (0.25 g, 0.0019 mol) with 2,6-difluorobenzaldehyde (1.2
equiv, 0.3240 g, 0.00228 mol) and piperidine (0.10 equiv, 0.0194 g, 0.000228 mol) and
EtOH (2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. Yellow
solid (0.3929 g, 79%) was collected via vacuum filtration. mp = 210-215 °C; Rf = 0.69
(EtOAc); 1H NMR (300 MHz, CDCl3-d1)  8.27 (s, 1H), 7.47-7.37 (m, 1H), 7.26 (s, 1H,
Hvinyl), 7.23 (d, J = 8.16 Hz, 1H), 7.05 (dd, J = 15.3 and 7.5 Hz, 1H), 6.89 (d, J = 7.84
Hz, 1H); 13C NMR : 167.53, 161.32-157.92 (dd, J = 7.02 Hz), 143.23, 132.29, 131.93 (t,
J = 10.44 Hz), 130.80, 123.09, 121.46, 120.70, 119.71, 112.25- 111.75 (d, J = 24.64 Hz),
112.16- 111.75 (t, J = 19.74 Hz), 110.12 ppm.
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(E)-3-(2,6-difluorobenzylidene)indolin-2-one (33) (Microwave Synthesis)
To a Glasschem 20 vessel with a stir bar was added 10 (0.5 g, 0.0038 mol) with 2,6difluorobenzaldehyde (1.2 equiv, 0.6480 g, 0.00456 mol) and piperidine (0.10 equiv,
0.0388 g, 0.000456 mol) and EtOH (4 mL). The power on the MARS Glasschem
Microwave was set to 300W, ramp to temp time = 2:00 min., hold temp = 5:00 min., set
temp = 140°C and stir bar speed = 3 (high). These parameters were collectively saved as
method name “Hagar”. Yellow solid (0.5369 g, 55.3%) was collected via vacuum
filtration. mp = 213-218 °C; Rf = 0.85 (EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.72
(s, 1H), 7.68-7.58 (m, 1H), 7.34 (d, J = 3.7 Hz, 1H), 7.31 (s, 1H, Hvinyl), 7.25 (d, J = 2.08
Hz, 1H), 6.89 (dd, J = 14.4 and 7.1 Hz, 1H); 13C NMR : 167.53, 161.32-157.92 (dd, J =
7.02 Hz), 143.23, 132.29, 131.93 (t, J = 10.44 Hz), 130.80, 123.09, 121.46, 120.70,
119.71, 112.25- 111.75 (d, J = 24.64 Hz), 112.16- 111.75 (t, J = 19.74 Hz), 110.12 ppm.
Anal. Calcd for C15H9NOF2: C, 70.04; H, 3.53; N, 5.45. Found: C, 69.90; H, 3.71; N,
5.62
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(E)-3-(3,5-difluorobenzylidene)indolin-2-one (34)
In a vial was combined 10 (0.2998 g, 0.0023 mol) with 3,5-difluorobenzaldehyde (1.2
equiv, 0.4170 g, 0.0027 mol) and piperidine (0.10 equiv, 0.023 g, 0.00027 mol, 27 L)
and EtOH (2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 hrs.
Golden solid (0.2819 g, 47.6%) was collected via vacuum filtration: mp = 202-205 °C; Rf
= 0.79 (EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.68 (s, 1H), 8.10 (d, J = 7.56 Hz,
1H), 7.72 (s, 1H, Hvinyl), 7.65 (d, J = 7.56 Hz, 1H, C-2‟), 8.14-8.01 (m, 1H), 6.98 (dd, J =
20.12 Hz, 9.15 Hz, 1H); Anal. Calcd for C15H9NOF2: C, 70.04; H, 3.53; N, 5.45. Found:
C, 69.65; H, 3.69; N, 5.42.

(E)-3-(2,3-dichlorobenzylidene)indolin-2-one (35)
In a vial was combined 10 (0.2497 g, 0.0019 mol) with 2,3-dichlorobenzaldehyde (1.2
equiv, 0.3945 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH
(2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow-orange
solid (0.4807 g, 89%) was collected via vacuum filtration: mp = 263-265 °C; Rf = 0.68
(50:50 Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.70 (s, 1H), 7.75 (d, J =
8.00 Hz, 1H), 7.72 (d, J = 7.64 Hz, 1H), 7.55 (s, 1H, Hvinyl), 7.51 (t, J = 7.93 Hz, 1H),
7.24 (t, J = 7.67 Hz, 1H), 7.07 (d, J = 7.64 Hz, 1H, C-6‟), 6.88 (d, J = 7.78 Hz, 1H), 6.81
(t, J = 7.64 Hz, 1H)
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(E)-3-benzylideneindolin-2-one (36)
In a vial was combined 10 (0.2515 g, 0.0019 mol) with benzaldehyde (1.2 equiv, 0.4283
g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) with
stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.3831 g, 62%)
was collected via vacuum filtration: mp = 172-175 °C (lit mp = 175-176 °C)30,31; Rf =
0.41 (50:50 Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.61 (s, 1H), 7.69 (d, J
= 7.26 Hz, 1H), 7.64 (s, 1H, Hvinyl), 7.49 (t, J = 7.62 Hz, 1H), 7.22 (t, J = 7.67 Hz, 1H),
6.88 (d, J = 7.98 Hz, 1H, C-2‟), 6.83 (t, J = 7.65 Hz, 1H).

(Z)-3-(4-nitrobenzylidene)indolin-2-one (37)
In a vial was combined 10 (0.2503 g, 0.0019 mol) with 4-nitrobenzaldehyde (1.2 equiv,
214 µL, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL)
with stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.2785 g,
68%) was collected via vacuum filtration: mp = 251-252 °C (lit mp = 252-253 °C)30; Rf =
0.41 (50:50 Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6) 10.68 (s, 1H), 8.32 (d, J
= 8.24 Hz, 1H, C-2‟), 7.93 (d, J = 8.19 Hz, 1H), 7.65 (s, 1H, Hvinyl), 7.39 (d, J = 8.24 Hz,
1H), 7.49 (d, J = 7.48 Hz, 1H), 7.25 (t, J = 7.42 Hz, 1H), 6.86 (t, J = 8.31 Hz, 1H)
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(Z)-3-(2-fluoro-5-nitrobenzylidene)indolin-2-one (38)
In a vial was combined 10 (0.2507 g, 0.0019 mol) with 2-fluoro-5-nitrobenzaldehyde (1.2
equiv, 0.3834 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH
(2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. A yellow solid
(0.3472 g, 65%) was collected via vacuum filtration: mp = 199-201 °C; Rf = 0.59 (50:50
Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6) 10.60 (s, 1H), 8.33 (s, 1H, C-6‟),
8.02 (d, J = 7.65 Hz, 1H), 7.64 (d, J = 8.42 Hz, 1H), 7.40 (d, J = 8.24 Hz, 1H), 7.33 (s,
1H, Hvinyl), 7.25 (d, J = 7.61 Hz, 1H), 6.84 (t, J = 7.84 Hz, 1H).

(E)-3-(2-chloro-3,6-difluorobenzylidene)indolin-2-one (39)
In a vial was combined 10 (0.2497 g, 0.0019 mol) with 2-chloro-3,6difluorobenzaldehyde (1.2 equiv, 0.3993 g, 0.0023 mol) and piperidine (0.10 equiv,
0.00023 mol, 23 L) and EtOH (2 mL) with stirring. The vial was placed on a 90 °C hot
plate for 3 h. A yellow solid (0.3472 g, 65%) was collected via vacuum filtration: mp =
199-201 °C; Rf = 0.59 (50:50 Hexanes:EtOAc); 1H NMR (300 MHz, DMSO-d6)  10.53
(s, 1H), 7.79 (d, J = 8.24 Hz, 1H), 7.54 (s, 1H, Hvinyl), 7.46 (d, J = 7.61 Hz, 1H), 7.22 (t, J
= 8.01 Hz, 1H), 7.17 (t, J = 7.57 Hz, 1H), 7.08 (d, J = 7.76 Hz, 1H), 6.95 (d, J = 7.24 Hz,
1H)
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(E)-3-(2,3,5-trichlorobenzylidene)indolin-2-one (40)
In a vial was combined 10 (0.2515 g, 0.0019 mol) with 2,3,5-trichlorobenzaldehyde (1.2
equiv, 0.4283 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH
(2 mL) with stirring. The vial was placed on a 90 °C hot plate for 3 h. An orange solid
(0.3831 g, 62%) was collected via vacuum filtration: mp = 268-270 °C; Rf = 0.60 (50:50
Hexanes:EtOAc); Compound 40 would not dissolve in any of the deuterated NMR
solvents, therefore an NMR spectrum could not be generated.

2,6-difluoro-3-nitrobenzaldehyde (42)
Sulfuric acid (11mL) was added to a beaker and cooled in an ice bath so that the
temperature did not exceed 5 °C. 2,6-Difluorobenzaldehyde (2.4 mL, 0.0222 mol) was
added to the beaker dropwise. Nitric acid (900 µL) was added to the beaker and the
solution was left to stir for 1 h. The product (off-white) was collected by vacuum
filtration (0.7104 g, 17%); mp = 59-61 °C; Rf = 0.62 (50:50 Hexanes:EtOAc); 1H NMR
(300 MHz, DMSO-d6) 10.20 (s, 1H), 8.56-8.48 (m, 1H), 7.51 (t, J = 9.51 Hz, 1H).
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(E)-3-(2,6-difluoro-3-nitrobenzylidene)indolin-2-one (43)
In a vial was combined 10 (0.2571 g, 0.0019 mol) with 42 (1.2 equiv, 0.4324 g, 0.0023
mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) with stirring.
The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.0705 g, 12%) was
collected via vacuum filtration: mp = 220-225 °C; Rf = 0.46 (50:50 Hexanes:EtOAc); 1H
NMR (300 MHz, DMSO-d6) 10.45 (s, 1H), 8.00 (d, J = 9.40 Hz, 1H), 7.70 (d, J = 7.49
Hz, 1H), 7.47 (s, 1H, Hvinyl), 7.23 (t, J = 7.66 Hz1H), 6.99 (t, J = 7.53 Hz, 1H), 6.83 (d,
J = 7.74 Hz, 1H), 6.59 (d, J = 9.41 Hz, 1H).


7-Nitroindolin-2-one (45)
In a vial was combined 8-nitroquinoline (1.9998 g, 0.0115 mol) with acetic acid (16 mL)
and 30% H2O2 (4 mL) and placed on a hot plate at 70 °C for 4 h. 30% H2O2 (4 mL) was
added and left on the hot plate at 70 °C for another 4 h. A brown solid (0.2898 g, 14%)
was collected via vacuum filtration: mp = 249-253 °C (lit mp = 256-257 °C)41; Rf = 0.16
(50:50 Hexanes:EtOAc); 1H and 13C NMR were not determined in time for this report.
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